{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:02:47Z","timestamp":1793930567727,"version":"4.8.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.autrev.2025.103773","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T18:58:14Z","timestamp":1739645894000},"page":"103773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: consensus statements from an international task force"],"prefix":"10.1016","volume":"24","author":[{"given":"Matteo","family":"Piga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahi","family":"Touma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Legge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel F.","family":"Ugarte-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihsane","family":"Hmamouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"G\u00f3mez Puerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Devilliers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacai","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Ziade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Mucke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Enrique","family":"Toro-Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Izuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Korsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ba\u00efdy S.Y.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Golder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin F.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Pons-Estel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Chasset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103773_bb0005","series-title":"Treat-to-target: Rheumatoid arthritis in adults: diagnosis and management: Evidence review C","author":"National Guideline Centre (UK)","year":"2018"},{"key":"10.1016\/j.autrev.2025.103773_bb0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103773_bb0015","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103773_bb0020","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","article-title":"Treat-to-target (T2T) recommendations for gout","volume":"76","author":"Kiltz","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0025","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0030","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2025.103773_bb0045","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0050","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.3390\/jcm12093348","article-title":"Treat-to-target in systemic lupus erythematosus: reality or pipe dream","volume":"12","author":"Zucchi","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2025.103773_bb0055","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","article-title":"Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med Res Methodol"},{"issue":"Suppl5","key":"10.1016\/j.autrev.2025.103773_bb0060","doi-asserted-by":"crossref","first-page":"v29","DOI":"10.1093\/rheumatology\/keaa382","article-title":"Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors","volume":"59","author":"Arnaud","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103773_bb0065","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1093\/rheumatology\/kez584","article-title":"Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort","volume":"59","author":"Piga","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103773_bb0070","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s13075-017-1451-5","article-title":"Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus","volume":"19","author":"Piga","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103773_bb0075","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/acr.24086","article-title":"Treatment target in newly diagnosed systemic lupus erythematosus: the association of lupus low disease activity state and remission with lower accrual of early damage","volume":"72","author":"Floris","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103773_bb0080","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1136\/ard-2022-222991","article-title":"Defining the targets in SLE management: insights and unmet gaps","volume":"81","author":"Zen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0085","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2217\/ijr.11.65","article-title":"Healthcare quality in systemic lupus erythematosus: using Donabedian\u2019s conceptual framework to understand what we know","volume":"7","author":"Lawson","year":"2012","journal-title":"Int J Clin Rheumatol"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2025.103773_bb0090","doi-asserted-by":"crossref","first-page":"i30","DOI":"10.1093\/rheumatology\/keac530","article-title":"Improving access to SLE therapies in low and middle-income countries","volume":"62","author":"Mendoza-Pinto","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103773_bb0095","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0277-9536(96)00221-3","article-title":"Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango)","volume":"44","author":"Charles","year":"1997","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.autrev.2025.103773_bb0100","article-title":"OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments","volume":"65","author":"Naye","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103773_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152381","article-title":"Consensus on the definitions and descriptions of the domains of the OMERACT core outcome set for shared decision making interventions in rheumatology trials","volume":"65","author":"D\u00e9cary","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103773_bb0110","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/art.42645","article-title":"Association between severe non-adherence to hydroxychloroquine and SLE flares, damage, and mortality in 660 patients from the SLICC inception cohort","volume":"75","author":"Nguyen","year":"2023","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103773_bb0115","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1007\/s12325-016-0394-6","article-title":"Patients\u2019 perspective of medication adherence in chronic conditions: a qualitative study","volume":"33","author":"Pag\u00e8s-Puigdemont","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.autrev.2025.103773_bb0120","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3390\/jcm11071857","article-title":"How can we enhance adherence to medications in patients with systemic lupus erythematosus? Results from a qualitative study","volume":"11","author":"Emamikia","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2025.103773_bb0125","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/09612033241228343","article-title":"The Type 1 & 2 systemic lupus erythematosus model: Perspectives of people living with systemic lupus erythematosus","volume":"33","author":"Eudy","year":"2024","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2025.103773_bb0130","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/rheumatology\/key398","article-title":"Predictors of fatigue and severe fatigue in a large international cohort of patients with systemic lupus erythematosus and a systematic review of the literature","volume":"58","author":"Arnaud","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103773_bb0135","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/rheumatology\/keaa671","article-title":"Patterns of fatigue and association with disease activity and clinical manifestations in systemic lupus erythematosus","volume":"60","author":"Arnaud","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103773_bb0140","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/ard-2023-224416","article-title":"EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis","volume":"83","author":"Parodis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0145","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/09612033221084515","article-title":"Use of telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak: the 6-month results of a randomized controlled trial","volume":"31","author":"So","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2025.103773_bb0150","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/rheumatology\/keab694","article-title":"Impact of teleconsultation on subsequent disease activity and flares in patients with systemic lupus erythematosus","volume":"61","author":"Au Eong","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103773_bb0155","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/rheumatology\/keab632","article-title":"Telemedicine in rheumatology: high specificity and sensitivity of follow-up virtual video consultations during COVID-19 pandemic","volume":"61","author":"Piga","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103773_bb0160","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00296-022-05224-y","article-title":"Digitally supported shared decision-making and treat-to-target in rheumatology: a qualitative study embedded in a multicenter randomized controlled trial","volume":"43","author":"Muehlensiepen","year":"2023","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2025.103773_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102864","article-title":"Digital health, big data and smart technologies for the care of patients with systemic autoimmune diseases: where do we stand?","volume":"20","author":"Bergier","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103773_bb0170","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2018-213512","volume":"77","author":"Pons-Estel","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0175","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1586\/17512433.2016.1146589","article-title":"Treat-to-target in systemic lupus erythematosus: are we there yet?","volume":"9","author":"Mok","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.autrev.2025.103773_bb0180","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2665-9913(22)00304-6","article-title":"Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study","volume":"4","author":"Kandane-Rathnayake","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103773_bb0185","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","article-title":"Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study","volume":"1","author":"Golder","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103773_bb0190","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1136\/annrheumdis-2015-207347","article-title":"Prolonged remission in Caucasian patients with SLE: prevalence and outcomes","volume":"74","author":"Zen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0195","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/acr.24464","article-title":"Prevalence, predictors, and prognostic benefits of remission achievement in patients with systemic lupus erythematosus: a systematic review","volume":"74","author":"Yang","year":"2022","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103773_bb0200","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard-2022-222487","article-title":"Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Ugarte-Gil","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0205","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1093\/rheumatology\/keac185","article-title":"Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus","volume":"61","author":"Emamikia","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103773_bb0210","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/acr.24009","article-title":"Better health-related quality of life in systemic lupus erythematosus predicted by low disease activity state\/remission: data from the Peruvian Almenara Lupus Cohort","volume":"72","author":"Ugarte-Gil","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2025.103773_bb0215","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/annrheumdis-2020-216965","article-title":"Lack of EULAR\/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis","volume":"79","author":"Moroni","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0220","article-title":"Effect of sustained clinical remission on the risk of lupus flares and impaired kidney function in patients with Lupus Nephritis","author":"Gatto","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2025.103773_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2023.101896","article-title":"Assessment of disease activity and damage in SLE: are we there yet?","volume":"37","author":"Cruciani","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103773_bb0230","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1093\/rheumatology\/keaa383","article-title":"Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties","volume":"59","author":"Chessa","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103773_bb0235","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/annrheumdis-2019-216753","article-title":"Laboratory investigation results influence Physician\u2019s Global Assessment (PGA) of disease activity in SLE","volume":"79","author":"Aranow","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0240","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002395","article-title":"Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus","volume":"8","author":"Mertz","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103773_bb0245","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(19)30105-5","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study","volume":"2","author":"Apostolopoulos","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103773_bb0250","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/annrheumdis-2020-217070","article-title":"Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort","volume":"79","author":"Saccon","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0255","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/S2665-9913(22)00107-2","article-title":"Physician Global Assessment International standardisation COnsensus in systemic Lupus Erythematosus: the PISCOS study","volume":"4","author":"Piga","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103773_bb0260","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3899\/jrheum.171307","article-title":"Practice variations in the diagnosis, monitoring, and treatment of systemic Lupus Erythematosus in Canada","volume":"45","author":"Keeling","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103773_bb0265","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard-2022-222487","article-title":"Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Ugarte-Gil","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0270","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1093\/rheumatology\/keab005","article-title":"Remission in SLE-do DORIS criteria match the treating physician\u2019s judgment? A cross-sectional study to assess reasons for discordance","volume":"60","author":"Mucke","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103773_bb0275","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/rheumatology\/kem016","article-title":"Treatment adherence and clinical outcome in systemic lupus erythematosus","volume":"46","author":"Chambers","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103773_bb0280","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.berh.2013.07.001","article-title":"Adherence to treatment in systemic lupus erythematosus patients","volume":"27","author":"Costedoat-Chalumeau","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103773_bb0285","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/art.42645","article-title":"Association between severe non-adherence to hydroxychloroquine and SLE flares, damage, and mortality in 660 patients from the SLICC inception cohort","volume":"75","author":"Nguyen","year":"2023","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103773_bb0290","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211073001","article-title":"Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge","volume":"14","author":"Dima","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0295","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1136\/annrheumdis-2012-202322","article-title":"Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)","volume":"72","author":"Costedoat-Chalumeau","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0300","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/annrheumdis-2020-218986","article-title":"2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice","volume":"80","author":"Ritschl","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"105","key":"10.1016\/j.autrev.2025.103773_bb0305","first-page":"S1","article-title":"Clinical Practice Guideline for the management of LUPUS NEPHRITIS","volume":"2024","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2025.103773_bb0310","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","article-title":"Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial","volume":"76","author":"Ordi-Ros","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0315","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/annrheumdis-2018-214427","article-title":"Lupus low disease activity state (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus","volume":"78","author":"Oon","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0320","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/ard-2022-222748","article-title":"Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus","volume":"82","author":"Morand","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 9","key":"10.1016\/j.autrev.2025.103773_bb0325","article-title":"Remission attainment in patients with systemic lupus erythematosus treated with anifrolumab compared with placebo over a 4-Year Period [abstract]","volume":"75","author":"van Vollenhoven","year":"2023","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103773_bb0330","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000516","article-title":"LUPUS-BEST-treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial","volume":"8","author":"Mucke","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2025.103773_bb0335","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/rheumatology\/keaa029","article-title":"Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study","volume":"59","author":"Morand","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103773_bb0340","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000700","article-title":"Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study","volume":"9","author":"Schlencker","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2025.103773_bb0345","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/acr.20397","article-title":"Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide","volume":"63","author":"Dall\u2019Era","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.autrev.2025.103773_bb0350","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000123","article-title":"A proteinuria cut-off level of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Sci Med"},{"issue":"11","key":"10.1016\/j.autrev.2025.103773_bb0355","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1093\/rheumatology\/keaa129","article-title":"Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis","volume":"59","author":"Parodis","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103773_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2023.101896","article-title":"Assessment of disease activity and damage in SLE: are we there yet?","author":"Cruciani","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103773_bb0365","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000542","article-title":"Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review","volume":"8","author":"Ugarte-Gil","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2025.103773_bb0370","doi-asserted-by":"crossref","unstructured":"Zen M, Iaccarino L, Gatto M, et al. The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients. Ann Rheum Dis;76:562-565.","DOI":"10.1136\/annrheumdis-2016-210154"},{"key":"10.1016\/j.autrev.2025.103773_bb0375","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0380","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000153","article-title":"First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort","volume":"3","author":"Ruiz-Irastorza","year":"2016","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2025.103773_bb0385","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002701","article-title":"Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study","volume":"8","author":"Floris","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103773_bb0390","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000173","article-title":"Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey","volume":"4","author":"Ngamjanyaporn","year":"2017","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2025.103773_bb0395","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.autrev.2017.05.017","article-title":"Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts","volume":"16","author":"Ruiz-Irastorza","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103773_bb0400","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jbspin.2020.03.008","article-title":"Is it possible to stop GCs in systemic lupus?","volume":"87","author":"Felten","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2025.103773_bb0405","article-title":"Is it safe to withdraw low-dose glucocorticoids in SLE patients in remission?","author":"Mathian","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103773_bb0410","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2019-216303","article-title":"Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial","volume":"79","author":"Mathian","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0415","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/acr2.11267","article-title":"Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus","volume":"3","author":"Tselios","year":"2021","journal-title":"ACR Open Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103773_bb0420","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000916","article-title":"Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience","volume":"5","author":"Tani","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103773_bb0425","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1177\/09612033211002269","article-title":"Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study","volume":"30","author":"Fasano","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2025.103773_bb0430","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2023-225369","article-title":"Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study","author":"Katsumata","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0435","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/rheumatology\/keac225","article-title":"Low-dose GCs withdrawn in systemic lupus erythematosus: a desirable and attainable goal","volume":"62","author":"Ji","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103773_bb0440","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/annrheumdis-2022-222435","article-title":"Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial","volume":"81","author":"Jourde-Chiche","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103773_bb0445","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2665-9913(23)00320-X","article-title":"Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial","volume":"6","author":"Chakravarty","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103773_bb0450","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/rheumatology\/kez422","article-title":"Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission","volume":"59","author":"Zen","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103773_bb0455","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/rheumatology\/keab373","article-title":"Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis","volume":"61","author":"Zen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103773_bb0460","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1016\/S2665-9913(23)00209-6","article-title":"Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study","volume":"5","author":"Cho","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103773_bb0465","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.autrev.2016.02.019","article-title":"Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review","volume":"15","author":"Floris","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103773_bb0470","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/09612033221074580","article-title":"The association between lupus serology and disease outcomes: A systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus","volume":"31","author":"Kostopoulou","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2025.103773_bb0475","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/rheumatology\/kead231","article-title":"SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus - an analysis of anti-double-stranded DNA monitoring","volume":"63","author":"Yeo","year":"2024","journal-title":"Rheumatology (Oxford)"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:04:00Z","timestamp":1741651440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225000333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":95,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1568997225000333"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103773","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: consensus statements from an international task force","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103773","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103773"}}